Oct 27 (Reuters) - The European Medicines Agency (EMA) on Friday said available evidence does not support a causal association between GLP-1 receptor agonist drugs, which include Novo Nordisk's weight loss treatment Wegovy, and thyroid cancer. (Reporting by Khushi Mandowara and Bhanvi Satija in Bengaluru; Editing by Varun H K)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
885.9 DKK | -0.08% | +1.29% | +27.00% |
Apr. 25 | NOVO NORDISK : JP Morgan gives a Buy rating | ZD |
Apr. 25 | Scholz promises support for pharma sector in Germany as Merck invests | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.00% | 566B | |
+25.83% | 661B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.92% | 231B | |
+5.03% | 200B | |
-9.41% | 195B | |
-6.26% | 145B | |
-11.77% | 144B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- EU regulator says no direct link between GLP-1 drugs and thyroid cancer